Depressive Disorder, Major Clinical Trial
Official title:
Evaluation of Clinical and Suicidal Behavior Characteristics Among Urban, Turkish Middle-Age Depressive Patients With Comorbid Adult Attention Deficit Hyperactivity Disorder
Verified date | October 2018 |
Source | Bozyaka Training and Research Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
In the presence of attention deficit hyperactivity disorder (ADHD) together with additional psychiatric diseases, the treatment process and prognosis of both ADHD and psychiatric comorbidity are adversely affected. The aim of this study is to compare the characteristics concerning the suicidal behavior of the patients with major depressive disorder (MDD) who have (ADHD+) or do not have (ADHD-) adult ADHD comorbidity and their responses to depression treatment. 96 inpatients were included in the study. Socio-demographic data form, Hamilton Depression Scale (HDRS), Wender Utah Rating Scale (WURS), Adult ADD/ADHD DSM IV- Based Diagnostic Screening and Rating Scale (A-ADHD), Personal and Social Performance Scale (PSP) were applied to the cases. In the study, depression starts at an early age in individuals with comorbid ADHD and the depression treatment progress changes negatively. This group of patients is at greater risk in terms of suicidal behavior. For these reasons, clinicians should be careful during ADHD and depression management in adults.
Status | Completed |
Enrollment | 96 |
Est. completion date | September 1, 2017 |
Est. primary completion date | June 1, 2017 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Complying with DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth) criteria for major depression 2. Hamilton Depression Scale (HDRS) being over 16 points during hospitalization Exclusion Criteria: 1. Mental retardation 2. Psychotic disorder 3. Alcohol or substance addiction 4. History of head trauma 5. Being under psychostimulant treatment |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Bozyaka Training and Research Hospital |
Agosti V, Chen Y, Levin FR. Does Attention Deficit Hyperactivity Disorder increase the risk of suicide attempts? J Affect Disord. 2011 Oct;133(3):595-9. doi: 10.1016/j.jad.2011.05.008. Epub 2011 Jun 11. — View Citation
Duran S, Fistikci N, Keyvan A, Bilici M, Çaliskan M. [ADHD in adult psychiatric outpatients: prevalence and comorbidity]. Turk Psikiyatri Derg. 2014 Summer;25(2):84-93. Turkish. — View Citation
Ekinci S, Öncü B, Canat S. Adult attention deficit hyperactivity disorder: comorbidity and functioning. Anadolu Psikiyatr Derg 2011;12:185-1.
Tamam L, Demirkol ME. Adult attention deficit/hyperactivity disorder and mood disorders. Turkiye Klin J Psychiatry-Special Top 2012;5:48-3.
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | depressive inpatients with comorbid ADHD (n=48) and without comorbid ADHD (n=48) were compared according to the suicidal behavior, the onset age of depression, the response to the treatment, and psychosocial functioning. | Clinical interviews, psychometric scales such as, Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), Hamilton Depression Rating Scale (HDRS), Adult ADD/ADHD DSM IV- Based Diagnostic Screening and Rating Scale (A-ADHDS), Wender Utah Rating Scale (WURS), Personal and Social Performance Scale (PSP) were applied. 96 inpatients were included in the study. In our study, depression starts at an early age in individuals with comorbid ADHD and the depression treatment progress changes negatively. This group of patients is at greater risk in terms of suicidal behavior. | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05915013 -
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
|
Phase 1 | |
Completed |
NCT04469322 -
Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression
|
N/A | |
Recruiting |
NCT05415397 -
Treating Immuno-metabolic Depression With Anti-inflammatory Drugs
|
Phase 3 | |
Recruiting |
NCT05988333 -
Psychoeducational Intervention for Families With a Member Affected by Major Depression
|
N/A | |
Completed |
NCT02919501 -
Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder
|
Phase 2 | |
Completed |
NCT00976560 -
Clinical Study to Test a New Drug to Treat Major Depression
|
Phase 2 | |
Recruiting |
NCT05518149 -
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
|
Phase 3 | |
Not yet recruiting |
NCT06303076 -
Tizanidine vs. Zolpidem in Primary Insomnia: A Randomized Trial
|
Phase 4 | |
Not yet recruiting |
NCT05901571 -
Acupuncture and Escitalopram for Treating Major Depression Clinical Study
|
N/A | |
Suspended |
NCT02546024 -
Predictors of Treatment Response in Late-onset Major Depressive Disorder
|
N/A | |
Completed |
NCT02452892 -
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
|
N/A | |
Completed |
NCT01583400 -
Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial
|
N/A | |
Completed |
NCT01407575 -
Buprenorphine for Treatment Resistant Depression
|
Phase 3 | |
Completed |
NCT01152996 -
Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study
|
Phase 3 | |
Enrolling by invitation |
NCT00762866 -
Psychiatric Genotype/Phenotype Project Repository
|
||
Completed |
NCT00366652 -
Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects
|
Phase 3 | |
Completed |
NCT00369343 -
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
|
Phase 3 | |
Completed |
NCT00384033 -
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT00149643 -
Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence
|
Phase 2 | |
Completed |
NCT00316160 -
Sexual Functioning Study With Antidepressants
|
Phase 4 |